Envestnet Portfolio Solutions Inc. Has $712,000 Holdings in ADMA Biologics Inc $ADMA

Envestnet Portfolio Solutions Inc. boosted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 223.0% in the 2nd quarter, Holdings Channel.com reports. The firm owned 39,084 shares of the biotechnology company’s stock after buying an additional 26,982 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in ADMA Biologics were worth $712,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Skandinaviska Enskilda Banken AB publ acquired a new position in ADMA Biologics during the 1st quarter valued at $35,000. SVB Wealth LLC acquired a new position in ADMA Biologics during the 1st quarter valued at $35,000. Toth Financial Advisory Corp raised its stake in ADMA Biologics by 1,081.6% during the 2nd quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 2,293 shares during the last quarter. Ameritas Advisory Services LLC acquired a new position in ADMA Biologics during the 2nd quarter valued at $46,000. Finally, Smartleaf Asset Management LLC raised its stake in ADMA Biologics by 161.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,493 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Trading Up 2.3%

Shares of ADMA stock opened at $14.69 on Tuesday. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The stock has a market cap of $3.51 billion, a price-to-earnings ratio of 17.08 and a beta of 0.47. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The firm has a fifty day moving average of $15.96 and a 200-day moving average of $18.33.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million during the quarter, compared to analysts’ expectations of $121.77 million. During the same quarter in the prior year, the company posted $0.13 EPS. The business’s revenue was up 13.8% on a year-over-year basis. On average, equities research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “buy (b-)” rating on shares of ADMA Biologics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $27.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.